* ICAD Inc ICAD.OQ reported a quarterly adjusted loss of 6
cents per share for the quarter ended in June, higher than the
same quarter last year, when the company reported EPS of -7
cents. The mean expectation of three analysts for the quarter
was for a loss of 7 cents per share. Wall Street expected
results to range from -7 cents to -6 cents per share.
* Revenue fell 14.3% to $5.03 million from a year ago;
analysts
expected $4.42 million.
* ICAD Inc's reported EPS for the quarter was a loss of 6
cents.
* The company reported a quarterly loss of $1.71 million.
* ICAD Inc shares had risen by 3.1% this quarter and
lost 24.3% so
far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 5.3%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the advanced
medical
equipment & technology peer group is also "buy"
Wall Street's median 12-month price target for ICAD Inc is $3.00
This summary was machine generated from LSEG data August 13 at
09:21 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.07 -0.06 Beat
Mar. 31 2024 -0.06 -0.05 Beat
Dec. 31 2023 -0.05 0.05 Beat
Sep. 30 2023 -0.09 -0.05 Beat